Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 13, 2000, Pages 4142-4149

  Di Girolamo, N ^a   Wakefield, D ^a   Coroneo, M T ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGED; ARTICLE; BOWMAN MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA CELL; CORNEA EPITHELIUM; ENZYME ASSAY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACRIMAL FLUID; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PTERYGIUM;

ADULT; AGED; AGED, 80 AND OVER; EYE PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROTEASE INHIBITORS; PTERYGIUM; TEARS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0033658370     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. The pathogenesis of pterygia
2. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells
3. Geographic distribution of pterygia
4. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells
5. Increased expression and activity of MMP-1 and MMP-3 by cultured pterygium head fibroblasts [ARVO Abstract]
6. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-β and tumor necrosis factor-α in the pterygium
7. Matrix metalloproteinases: Structures, evolution, and diversification
8. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
9. The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis
10. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix
11. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors
12. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium
13. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts
14. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis
15. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
16. Pterygia pathogenesis: Corneal invasion by matrix metalloproteinase (MMP) expressing altered limbal basal stem cells and activation of fibroblasts [ARVO Abstract]
17. Microscopic localization of active proteases by in situ zymography: Detection of matrix metalloproteinase activity in vascular tissue
18. Expression of degradative enzymes and protease inhibitors in corneas with keratoconus
19. Tissue inhibitor of metalloproteinase-3 is a component of Bruch's membrane of the eye
20. Immunohistochemical localisation of matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma
21. Binding of gelatinases A and B to type-1 collagen and other matrix components
22. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms
23. Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression
24. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases: Role of the fibronectin type II-like repeats
25. Matrix metalloproteinase-2 is an interstitial collagenase
26. Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas
27. Characterization of the major matrix degrading metalloproteinase of human corneal stroma: Evidence for an enzyme/inhibitor complex
28. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing
29. Mechanism of cell surface activation of 72-kDa type IV collagenase
30. Recombinant TIMP-1 and -2 enhance the proliferation of rabbit corneal epithelial cells in vitro and the spreading of rabbit corneal epithelium in situ
31. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinase-1
32. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
33. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro
34. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium
35. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
36. Capillaries in the epithelium of pterygium
37. Peripheral light focusing by the anterior eye and the ophthalmohelioses
38. A model for pterygium formation
39. Gelatinase concentration in tears of corneal-grafted patients
40. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein clearance in ocular rosacea
41. Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases
42. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor
43. The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU)